Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Mil-101 Magnetic Nanocarrier for Solid-Phase Delivery of Doxorubicin to Breast and Lung Cancer Cells Publisher Pubmed



Taheriledari R1 ; Ghaforigorab M1 ; Ramezanpour S2 ; Mahdavi M3 ; Safavi M4 ; Akbarzadeh AR5 ; Maleki A1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Catalysts and Organic Synthesis Research Laboratory, Department of Chemistry, Iran University of Science and Technology, Tehran, 16846-13114, Iran
  2. 2. Department of Chemistry, K. N. Toosi University of Technology, P.O. Box 15875-4416, Tehran, Iran
  3. 3. Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Department of Biotechnology, Iranian Research Organization for Science and Technology (IROST), P. O. Box 3353-5111, Tehran, Iran
  5. 5. Department of Chemistry, Iran University of Science and Technology, PO Box: 16846-13114, Tehran, Iran

Source: International Journal of Biological Macromolecules Published:2024


Abstract

An efficient strategy for passive delivery of doxorubicin (DOX) to the breast (MDA-MB-231) and lung (A-549) cancer cells is presented and compared with MCF-10A normal breast cells. Two versions of a peptide structure (linear and cyclic) have been designed and assessed. The molecular dynamic simulations in Material Studio2017 exhibited a higher adsorption capacity for L2 (cyclic version) compared with the adsorption capacity of L1 (linear version) on the PG surface by electrostatic interactions between guanidine of arginine and –OH of PG. The prepared final product based on iron oxide nanoparticles and MIL-101(Fe) (formulated as DOX@Fe3O4/MIL-101–(C,L)C[RW]3) is characterized and the drug content has been estimated. The release profiles revealed an ultra-fast stimulus-sensitive model in acidic media, which corroborates a pH-triggered release. The in vitro assessments disclosed that aggregation of nanocargo around the cancer cells and resulted toxicity are more than the neat DOX in the same dosage as DOX@Fe3O4/MIL-101–CC[RW]3. The obtained distinguished features lie in ability to utilize a biocompatible nanocargo structure to release an appropriate dose of DOX in a controlled manner in the cancer cell environment. Moreover, the functionalization of MIL-101 using cyclic and linear peptides and their comparison is one of the important features of this project. © 2024 Elsevier B.V.